Please assess the completion status of the following clinical trial:

Trial Title: Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of RA and requiring Tocilizumab therapy~* Subject has provided written informed consent~Exclusion Criteria:~* Corticosteroid therapy (10 mg/day of prednisone or equivalent)~* Pregnant or lactating women~* Uncontrolled type 1 or type 2 diabetes~* Uncontrolled dyslipidemia~* Elevated transaminases (\> three times higher than the normal range)~* History of diverticulitis or intestinal perforation~* Tocilizumab contraindications: Severe or active infections, Hypersensitivity to the active substance or to any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Adiponectin evaluation (Type: EXPERIMENTAL): Patients evaluated for serum adiponectin level and for body composition before each infusion of Tocilizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).